BioSpace News Archive

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, is delivering three presentations related to the company’s neoantigen vaccine programs and capabilities at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

RELIEF THERAPEUTICS Holding SA announced positive 12-month stability data for the liquid and lyophilized preparations of RLF-100 ®, intended for intravenous and inhaled administration.

Complement Therapeutics GmbH, a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases, announced the completion of a €72 million Series A financing.

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, presented promising preclinical data on its novel oncolytic virus TG6050, at the American Association for Cancer Research Annual Meeting, April 14-19, 2023.

Glycotope GmbH announces that it will present its glyco-engineered cell lines in a poster presentation at the 2022 American Association for Cancer Research Meeting, being held in Orlando, Florida, United States, between 14-19 April 2023.

Genmab A/S and argenx announced that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas.

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, released preclinical data on TALEN®-edited MUC1 CAR T-cells at the American Association for Cancer Research Annual Meeting 2023.

Medivir AB announces that a poster entitled ‘A triple combination of fostrox with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo,’ will be presented at the American Association for Cancer Research Annual Meeting by Fredrik Öberg, CSO at Medivir.

Amneal Pharmaceuticals, Inc. announced certain unaudited preliminary financial results for the first quarter ended March 31, 2023.

Passage Bio, Inc. (NASDAQ: PASG) today announced that William Chou, M.D., chief executive officer, and Alex Fotopoulos, chief technical officer, will participate in a virtual fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023 at 3:30 p.m. ET.